Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Lexeo Therapeutics Inc (NASDAQ: LXEO) closed at $2.82 down -8.44% from its previous closing price of $3.08. In other words, the price has decreased by -$8.44 from its previous closing price. On the day, 0.48 million shares were traded. LXEO stock price reached its highest trading level at $3.0589 during the session, while it also had its lowest trading level at $2.81.
Ratios:
For a deeper understanding of Lexeo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.42 and its Current Ratio is at 3.42. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on June 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $28.
On June 06, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $22.
On November 28, 2023, Stifel started tracking the stock assigning a Buy rating and target price of $20.Stifel initiated its Buy rating on November 28, 2023, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 16 ’25 when Townsend Richard Nolan sold 1,074 shares for $2.77 per share. The transaction valued at 2,979 led to the insider holds 221,173 shares of the business.
Adler Eric sold 585 shares of LXEO for $1,623 on May 16 ’25. The Chief Medical Officer now owns 67,681 shares after completing the transaction at $2.77 per share. On May 16 ’25, another insider, Robertson Jenny, who serves as the Chief Legal Officer of the company, sold 521 shares for $2.77 each. As a result, the insider received 1,445 and left with 63,098 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXEO now has a Market Capitalization of 93601152 and an Enterprise Value of 3158267.
Stock Price History:
The Beta on a monthly basis for LXEO is 0.88, which has changed by -0.81200004 over the last 52 weeks, in comparison to a change of 0.09362543 over the same period for the S&P500. Over the past 52 weeks, LXEO has reached a high of $19.50, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is -9.98%, while the 200-Day Moving Average is calculated to be -56.52%.
Shares Statistics:
For the past three months, LXEO has traded an average of 972.63K shares per day and 843580 over the past ten days. A total of 33.19M shares are outstanding, with a floating share count of 25.01M. Insiders hold about 24.67% of the company’s shares, while institutions hold 82.00% stake in the company. Shares short for LXEO as of 1745971200 were 3264722 with a Short Ratio of 3.36, compared to 1743379200 on 2579137. Therefore, it implies a Short% of Shares Outstanding of 3264722 and a Short% of Float of 11.4700004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Lexeo Therapeutics Inc (LXEO) is currently shaped by the ongoing analysis conducted by 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.46 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.22 and -$3.29 for the fiscal current year, implying an average EPS of -$2.86. EPS for the following year is -$2.21, with 5.0 analysts recommending between -$1.6 and -$2.69.
